- Companies
- Beijing Yuan Xin
Beijing Yuan Xin Funding, Investors & Competitors
Beijing Yuan Xin has raised $850M across 4 funding rounds, most recently a $232M Series F in August 2021.
Last Beijing Yuan Xin funding round
$232M
Series F · Aug 2021
Cumulative funding Beijing Yuan Xin raised
$850M
across 4 funding rounds
Key investors in Beijing Yuan Xin
HSG
CITIC Securities
Qiming Venture Partners
Tencent
INCE Capital
Index Capital
Sequoia Capital
OrbiMed
About Beijing Yuan Xin
Beijing Yuan Xin is a Beijing-based technology company operating an integrated healthcare platform for pharmaceutical distribution and health insurance services. It connects suppliers, pharmacies, and insurers to streamline drug supply chains and reimbursement processes across China.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Beijing Yuan Xin Funding History
Beijing Yuan Xin has raised a total of $850M across 4 funding rounds.
Beijing Yuan Xin's first fundraising round was a $73M Series C in January 2019. The most recent completed round was a $232M Series F in August 2021.
Beijing Yuan Xin funding rounds
| Date | Stage | Investors | Raised |
|---|---|---|---|
| Aug 2021 | Series F | Hel Ved Capital; Kun Ling Capital; Index Capital; Future Innovation Fund; Sequoia Capital; BOCI Asia; Archerman Capital; OrbiMed; B Capital; eFund; CITIC Securities; INCE Capital | $232M |
| Feb 2021 | Series E | HSG (lead); Tencent (lead); Qiming Venture Partners; CICC Capital; CITIC Securities | $465M |
| Jun 2020 | Series D | Index Capital; Qiming Venture Partners; CITIC Securities; HSG; INCE Capital | $80M |
| Jan 2019 | Series C | Tencent (lead); HSG | $73M |
Who has invested in Beijing Yuan Xin?
16 investors have backed Beijing Yuan Xin across its funding rounds, including HSG, CITIC Securities, Qiming Venture Partners, Tencent, INCE Capital and Index Capital.
Lead investors include HSG and Tencent.
Beijing Yuan Xin Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Jun 2020 | ||
| 3 | Lead | Jan 2019 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Lead | Jan 2019 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 1 | Participant | Aug 2021 | ||
| 1 | Participant | Aug 2021 | ||
| 1 | Participant | Aug 2021 | ||
| 1 | Participant | Feb 2021 | ||
| 1 | Participant | Aug 2021 | ||
| 1 | Participant | Aug 2021 | ||
| 1 | Participant | Aug 2021 | ||
This data is available for Pro users. Sign up to see all 16 Beijing Yuan Xin investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBeijing Yuan Xin Competitors
Beijing Yuan Xin competitors include listed companies like IQVIA, IDEXX Laboratories, GE HealthCare and ICON plc, and private ones like Benchling and Commure.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | $210M | - | $6.1B | 29.0x | ||
| Private | $200M | - | $7B | 35.0x |
Beijing Yuan Xin Public Comps
Beijing Yuan Xin is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, Amgen, Novo Nordisk and Gilead Sciences.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
| $37B | $17B | 6.8x | 6.5x | 14.8x | 14.4x | |||
This data is available for Pro users. Sign up to see all Beijing Yuan Xin competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Beijing Yuan Xin
| When was Beijing Yuan Xin founded? | Beijing Yuan Xin was founded in 2015. |
| Where is Beijing Yuan Xin headquartered? | Beijing Yuan Xin is headquartered in Beijing, China. |
| Is Beijing Yuan Xin publicly listed? | No, Beijing Yuan Xin is a private, VC-backed company. |
| How much funding has Beijing Yuan Xin raised? | Beijing Yuan Xin has raised $850M across 4 funding rounds. |
| What was Beijing Yuan Xin's last funding round? | Beijing Yuan Xin's last funding round was a $232M Series F in August 2021. |
| Who are Beijing Yuan Xin's investors? | Beijing Yuan Xin's investors include CITIC Securities, HSG, Index Capital, Tencent, Qiming Venture Partners, INCE Capital, Hel Ved Capital, Kun Ling Capital, Future Innovation Fund, CICC Capital and 6 others. |
| Which companies are comparable to Beijing Yuan Xin? | Companies comparable to Beijing Yuan Xin include IQVIA, IDEXX Laboratories, GE HealthCare, ICON plc, Benchling and Commure. |
See companies similar to Beijing Yuan Xin
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




